Bio-Rad Laboratories, Inc. BIO.B

365.08 0.00 0.00% as of 24 Sep
Market cap
$10.3B
P/E
43.8×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
2,583.20 2,566.50 2,671.20 2,802.20 2,922.55 2,545.63 2,311.66 2,289.42 2,160.15 2,068.17
Revenue Growth
0.65% (3.92%) (4.67%) (4.12%) 14.81% 10.12% 0.97% 5.98% 4.45% 2.41%
Cost of Revenue
1,243.30 1,187.60 1,244.30 1,234.90 1,284.45 1,107.74 1,054.66 1,066.26 972.45 929.74
Gross Profit
1,339.90 1,378.90 1,426.90 1,567.30 1,638.10 1,437.89 1,257.00 1,223.15 1,187.70 1,138.43
R&D Expenses
— — 247.43 256.89 260.64 217.76 202.71 199.20 250.16 205.71
SG&A Expenses
844.30 814.00 841.70 827.80 877.12 798.80 824.63 834.78 806.79 814.70
Operating Income
47.20 269.00 337.80 482.60 500.34 421.33 229.66 (103.34) 119.25 55.72
Non-operating Income/Expense
948.30 (2,611.50) (1,187.90) (5,186.80) 4,948.72 4,496.68 2,031.42 616.00 (21.44) (14.16)
Non-operating Interest Expenses
49.00 48.90 49.40 38.10 1.55 21.86 23.42 23.96 23.01 23.38
EBT
995.50 (2,342.50) (850.10) (4,704.20) 5,449.06 4,918.01 2,261.08 512.66 97.81 41.56
Income Tax Provision
235.60 (498.30) (212.80) (1,076.70) 1,194.80 1,103.78 502.41 147.05 (24.44) 15.56
Income after Tax
759.90 (1,844.20) (637.30) (3,627.50) 4,254.26 3,814.23 1,758.68 365.61 122.25 26.00
Net Income Common
759.90 (1,844.20) (637.30) (3,627.50) 4,254.26 3,814.23 1,758.68 365.61 122.25 26.00
EPS (Basic)
27.87 (65.36) (21.82) (121.79) 142.33 127.86 58.93 12.10 3.87 0.96
EPS (Diluted)
27.85 (65.36) (21.82) (121.79) 140.56 126.20 58.27 11.94 3.82 0.95
Shares (Basic, Weighted)
27.26 28.21 29.21 29.79 29.83 29.77 29.84 29.84 29.66 29.44
Shares (Diluted, Weighted)
27.28 28.21 29.21 29.79 30.21 30.16 30.18 30.23 30.03 29.65
Gross Margin
51.87% 53.73% 53.42% 55.93% 56.05% 56.48% 54.38% 53.43% 54.98% 55.05%
EBIT Margin
1.83% 10.48% 12.65% 17.22% 17.12% 16.55% 9.93% (4.51%) 5.52% 2.69%
EBT margin
38.54% (91.27%) (31.82%) (167.88%) 186.45% 193.19% 97.81% 22.39% 4.53% 2.01%
Net Profit Margin
29.42% (71.86%) (23.86%) (129.45%) 145.57% 149.83% 76.08% 15.97% 5.66% 1.26%
Free Cash Flow Margin
14.51% 11.29% 8.18% 2.87% 18.33% 18.85% 15.93% 6.99% (0.50%) 3.62%
EBITDA
47.20 269.00 337.80 482.60 500.34 421.33 229.66 (103.34) 119.25 55.72
EBIT
47.20 269.00 337.80 482.60 500.34 421.33 229.66 (103.34) 119.25 55.72
Income from Continuous Operations
759.90 (1,844.20) (637.30) (3,627.50) 4,254.26 3,814.23 1,758.68 365.61 122.25 26.00
Consolidated Net Income/Loss
759.90 (1,844.20) (637.30) (3,627.50) 4,254.26 3,814.23 1,758.68 365.61 122.25 26.00
EPS (Basic, from Continuous Ops)
27.87 (65.36) (21.82) (121.79) 142.61 128.13 58.93 12.25 4.12 0.88
EPS (Basic, Consolidated)
27.87 (65.36) (21.82) (121.79) 142.61 128.13 58.93 12.25 4.12 0.88
EPS (Diluted, from Cont. Ops)
27.85 (65.36) (21.82) (121.79) 140.83 126.47 58.27 12.10 4.07 0.88
Shares (Diluted, Average)
27.28 28.21 29.21 29.79 30.21 30.16 30.18 30.23 30.03 29.65
EPS (Diluted, Consolidated)
27.85 (65.36) (21.82) (121.79) 140.83 126.47 58.27 12.10 4.07 0.88
EBITDA Margin
1.83% 10.48% 12.65% 17.22% 17.12% 16.55% 9.93% (4.51%) 5.52% 2.69%
Operating Cash Flow Margin
20.60% 17.74% 14.03% 6.94% 22.91% 22.98% 19.81% 12.47% 4.82% 10.45%

Fold the line items

In millions of $ except per-share values · columns are period end dates